氯雷他定对哮喘儿童P-选择素表达的抑制作用及临床意义  

Inhibitory effect of loratadine on the expression of p-selectin and its clinical significance in asthmatic children

作　　者：钱耀琴[1] 顾洪亮[1] 张少明[1] 王平[1] 胡建芬[1] 

机构地区：[1]上海第二医科大学附属第九人民医院儿科,200011

出　　处：《临床儿科杂志》2000年第2期72-73,共2页Journal of Clinical Pediatrics

摘　　要：为评价氯雷他定对哮喘儿童血浆P-选择素表达的抑制作用及临床应用的意义。应用^(125)I-SZ-51标记的特异性单克隆抗体放免法,测定60例急性发作期和缓解期哮喘患儿血浆P-选择素水平。随机分成治疗组(30例),采用吸入激素+氯雷他定治疗×24周;对照组(30例)单用吸入激素治疗。结果显示:缓解期,治疗组血浆P-选择素水平、肺功能、临床综合评分均较对照组明显下降和改善,差异显著(P均<0.01)。提示氯雷他定具有抑制P-选择素表达的作用,能有效地减轻变应性炎症,改善哮喘儿童的临床症状和肺功能,可作为辅佐治疗儿童支气管哮喘的药物之一。To evaluate the inhibitory effect of loratadine on the expression of p-selectin and its clinical significance in asthmatic children, the plasma p-selectin level was determined by radioimmunoassy of specific McAB with 125I - SZ - 51 marked in 60 asthmatic children both at their acute and relieved stages. 30 of them received both oral loratadine and inhaled corticosteroids for 24 weeks as a treat group t and another 30 cases were just given inhaled corticosteroids as a control group. The results showed that the plasma p-selectin level was significantly decreased and the lung function and the clinical comprehensive scores were remarked improved in the treat group comparing with that in the control group (all P<0. 01). It is suggested that loratadine will be available to inhibit the p-selectin expression, to relieve the airway allergic inflammation, and to improve the lung function and clinical symptoms as one of adjunctive medicines for asthmatic children.

关 键 词：氯雷他定 P-选择素 哮喘 儿童 

分 类 号：R725.6[医药卫生—儿科]